At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
A3309drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of Elobixibat in Patients With Chronic Idiopathic Constipation
In Brief
A Phase 2 clinical trial evaluating A3309 for Constipation and Chronic Constipation. Completed, enrolled 190 participants across 44 sites.
Detailed Summary
The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation, Chronic Constipation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedNov 2009
Primary CompletionOct 2010
TodayJul 2026
First PostedNov 3, 2009
Enrollment StartNov 1, 2009
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.7 years ago
Interventions
A3309drug
A3309 in three different dosage levels or placebo once daily for the duration of the study